Clinicaltrials.gov identifier:
NCT02206360 (https://clinicaltrials.gov/show/NCT02206360)
Prevention
Study Contact Information:
Lisa Schuldt, BSN
914-849-7582
[email protected]
This is a study looking at esophageal ultrasound as a screening for pancreatic cancer in high risk individuals. The study will enroll people with an inherited risk for cancer due to a BRCA2 or CDKN2A mutation with or without a family history of pancreatic cancer. The study will also enroll people with a first- or second-degree relative with pancreatic cancer with Lynch syndrome (MLH1, MSH2, PMS2, MSH6, EPCAM) or any of the following mutations BRCA1, P53, PALB2, APC, or ATM.
Enrolled subjects will undergo Endoscopic Ultrasound (EUS) alternating with Magnetic Resonance Imaging (MRI), every six to 12 months, for up to 5 years.
White Plains, NY
White Plains Hospital
Lisa Schuldt, BSN by phone: 914-849-7582 or email [email protected]
Principal Investigator: Joshua P Raff, MD
People at elevated risk for pancreatic cancer
Patients are excluded if they have:
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.